# Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

> **NCT00089349** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Childhood Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** methotrexate
- **DRUG:** mercaptopurine

## Key facts

- **NCT ID:** NCT00089349
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-09
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089349, "Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00089349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*